Search Results - Boards

Ticker	Board	Posts	Status	Last Post	Category
PROG	Progenity Inc	1,456		2 years ago	Biotechs
	Tornado Alley (PROG)	517,841		1 hour ago	Politics
PLAN	PROGRESSIVE PLANET SOLUTIONS INC	331		1 day ago	Mining/Resources
	ProGreen US Inc. (fka PGUS)	58,283		4 days ago	Delisted
PGR	Progressive Corporation	143		1 month ago	Insurance
	Progressive Care Inc (fka RXMD)	196,265		1 month ago	Delisted
ARC	American Reprographics Company	22		3 months ago	Retail - Chains
PRGS	Progress Software Corporation	5		8 months ago	Computers - Software
SERA	Sera Prognostics Inc	4		1 year ago	Biotechs
	Web Trends: Software & Programming (fka WEBT)	23		1 year ago	Delisted
	Progressive Stocks	18,067		1 year ago	User's Groups
	Liberals and Progressives (libs)	26		1 year ago	Politics
CPSI	Computer Programs and Systems Inc.	8		1 year ago	Computers - Software
PROGEUST	Protector Roge	2		3 years ago	Coins
	Progress Energy Inc. (fka PREX)	16		3 years ago	Delisted
	Proguard Acquisition Corp. (fka PGRD)	241		4 years ago	Delisted
	FreeLoadr - New Video Game Program	6		4 years ago	Coffee Shop
	iHub Investor Relations Professional (IRP)/Commerc	1,715	Closed.	4 years ago	Welcome to InvestorsHub
PGNX	Progenics Pharmaceuticals Inc.	796		5 years ago	Biotechs
PGNY	Progyny Inc.	7		5 years ago	Insurance
ASHXF	Progressive Planet Solutions Inc.	4		5 years ago	Mining/Resources
	Pharmco a Division of Progressive Care (fka RXMDP)	33		6 years ago	Delisted
HEALTHYUSD	HealthyFoodProgram	0		7 years ago	Coins
	pilgrim's progress	6,632		8 years ago	Technical Analysis
	Progressive Green Solutions Inc. (fka PGSC)	66		8 years ago	Delisted
	Progressive Gaming (fka PGICQ)	24		8 years ago	Delisted
	Proginet Corp. (fka PRGF)	3		14 years ago	Delisted
	FATAL - a trading program	4		16 years ago	User's Groups
	MICROCAP TRADER PROGRAM	19		17 years ago	Support Forums
	Programing (PRGM)	682		18 years ago	Other
PGLAF	Progen Industries	2		18 years ago	Biotechs

Ticker

Board

Posts

Status

Last Post

Category

PROG

Progenity Inc

1,456

2 years ago

Biotechs

Tornado Alley (PROG)

517,841

1 hour ago

Politics

PLAN

PROGRESSIVE PLANET SOLUTIONS INC

331

1 day ago

Mining/Resources

ProGreen US Inc. (fka PGUS)

58,283

4 days ago

Delisted

PGR

Progressive Corporation

143

1 month ago

Insurance

Progressive Care Inc (fka RXMD)

196,265

1 month ago

Delisted

ARC

American Reprographics Company

3 months ago

Retail - Chains

PRGS

Progress Software Corporation

8 months ago

Computers - Software

SERA

Sera Prognostics Inc

1 year ago

Biotechs

Web Trends: Software & Programming (fka WEBT)

1 year ago

Delisted

Progressive Stocks

18,067

1 year ago

User's Groups

Liberals and Progressives (libs)

1 year ago

Politics

CPSI

Computer Programs and Systems Inc.

1 year ago

Computers - Software

PROGEUST

Protector Roge

3 years ago

Coins

Progress Energy Inc. (fka PREX)

3 years ago

Delisted

Proguard Acquisition Corp. (fka PGRD)

241

4 years ago

Delisted

FreeLoadr - New Video Game Program

4 years ago

Coffee Shop

iHub Investor Relations Professional (IRP)/Commerc

1,715

Closed.

4 years ago

Welcome to InvestorsHub

PGNX

Progenics Pharmaceuticals Inc.

796

5 years ago

Biotechs

PGNY

Progyny Inc.

5 years ago

Insurance

ASHXF

Progressive Planet Solutions Inc.

5 years ago

Mining/Resources

Pharmco a Division of Progressive Care (fka RXMDP)

6 years ago

Delisted

HEALTHYUSD

HealthyFoodProgram

7 years ago

Coins

pilgrim's progress

6,632

8 years ago

Technical Analysis

Progressive Green Solutions Inc. (fka PGSC)

8 years ago

Delisted

Progressive Gaming (fka PGICQ)

8 years ago

Delisted

Proginet Corp. (fka PRGF)

14 years ago

Delisted

FATAL - a trading program

16 years ago

User's Groups

MICROCAP TRADER PROGRAM

17 years ago

Support Forums

Programing (PRGM)

682

18 years ago

Other

PGLAF

Progen Industries

18 years ago

Biotechs

Play Episode

11min

Proactive - Interviews for investors

West Cobar Metals' high-grade copper discovery: Bulla Park delivers exceptional results

West Cobar Metals Ltd (ASX:WC1) managing director Matt Szwedzicki talked with Proactive's Jonathan Jackson about the company’s latest metallurgical results from the Bulla Park project. Early-stage testing has delivered high-grade copper, silver, and antimony concentrates with strong recoveries. Szwedzicki described the initial float test results as amazing. A key challenge at Bulla Park has been the presence of tetrahedrite, a less common mineral in Australia. However, recent testing has demonstrated successful separation and recovery processes. The company has now achieved 88% extraction of antimony, a commodity that has surged in value due to reduced exports from China. Szwedzicki also discussed West Cobar’s broader strategy, including plans to optimise metallurgical processes, assess a mineral resource estimate, and advance drilling at Bulla Park. Beyond this, the company is progressing its Salazar project in Western Australia, which holds rare earths, scandium, and alumina resources. The recent acquisition of the Mystique Gold Project further strengthens West Cobar’s portfolio, adding a promising gold exploration target. Stay tuned for more updates from West Cobar Metals. If you enjoyed this interview, give the video a like, subscribe to Proactive’s YouTube channel, and turn on notifications for the latest mining insights. #WestCobarMetals #Copper #Antimony #Mining #ASX #BullaPark #RareEarths #GoldExploration #Metals #Investing #Resources

Proactive - Interviews for investors

Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April

Immunic Therapeutics Chief Scientific Officer Dr. Hella Kohlhof joined Steve Darling from Proactive to discuss the company’s progress in developing vidofludimus calcium, a novel treatment designed to combat multiple sclerosis (MS) through a unique dual mode of action. The drug offers neuroprotection, anti-inflammatory effects, and antiviral benefits, addressing key aspects of MS pathology. Dr. Kohlhof emphasized the urgent need for therapies that prevent disability progression in MS patients, helping them maintain independence for as long as possible. She explained that vidofludimus calcium achieves this by activating Nurr1 to promote neuroprotection while simultaneously inhibiting DHODH, reducing inflammation and Epstein-Barr virus (EBV) reactivation—both believed to play a role in MS development and progression. A major milestone for Immunic Inc. is approaching, with the phase 2 CALLIPER trial readout expected in April 2025. This study aims to confirm the drug’s neuroprotective effects, positioning it as a potential disease-modifying treatment for MS. Dr. Kohlhof also highlighted vidofludimus calcium’s strong safety and tolerability profile, noting that it is a once-daily oral tablet that requires no treatment monitoring, making it a convenient option for patients. Looking ahead, Immunic is also advancing phase 3 ENSURE trials for relapsing MS, expected to complete in 2026. With limited treatment options for progressive MS, Dr. Kohlhof underscored the high unmet medical need and the potential impact of vidofludimus calcium on improving patient outcomes worldwide. #proactiveinvestors #immunicinc #nasdaq #imux #MSResearch #VidofludimusCalcium #Neuroprotection #ImmunicInc #MSAwareness #CALLIPERTrial #MSBreakthrough #MSDisability #ClinicalTrials

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Proactive - Interviews for investors

Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data

Immunic Therapeutics chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company's strong presence at the 10th annual ACTRIMS Forum, where it presented two key posters on multiple sclerosis (MS). He highlighted that Immunic’s investigational drug, vidofludimus calcium, has potential neuroprotective properties that may benefit both relapsing and progressive MS patients. One of the posters examined baseline characteristics of past progressive MS trials and contrasted them with Immunic’s CALLIPER trial, designed for non-relapsing patients with minimal inflammatory activity. The second poster explored preclinical data on the drug’s mechanism of action, emphasizing its potential to target activated microglia and support neuron survival. Muehler noted significant engagement from the MS community at ACTRIMS, with many keenly anticipating the CALLIPER trial’s readout in April. “It’s really one of the very few late-stage drugs with a potential neuroprotective effect,” he said, adding that the data could provide new hope for progressive MS patients who currently have limited treatment options. Stay tuned for more updates on Immunic’s progress. For more interviews, subscribe to Proactive’s YouTube channel, like this video, and turn on notifications! #ImmunicTherapeutics #MSResearch #Neuroprotection #CALLIPERTrial #MultipleSclerosis #Biotech #DrugDevelopment #ClinicalTrials #MedicalBreakthrough #ACTRIMS

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Board Search Results

Board Search Results

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Board Search Results

Board Search Results

Go Ad-Free